LAVA Therapeutics N.V. (LVTX)
1.35
-0.03 (-2.17%)
At close: Apr 25, 2025, 12:53 PM
-2.17% (1D)
| Bid | 0.99 |
| Market Cap | 35.51M |
| Revenue (ttm) | 11.98M |
| Net Income (ttm) | -25.11M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.44 |
| Forward PE | -1.28 |
| Analyst | Hold |
| Ask | 1.63 |
| Volume | 21,953 |
| Avg. Volume (20D) | 411,404 |
| Open | 1.37 |
| Previous Close | 1.38 |
| Day's Range | 1.28 - 1.37 |
| 52-Week Range | 0.85 - 3.20 |
| Beta | 0.45 |
About LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for b...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 34
Stock Exchange NASDAQ
Ticker Symbol LVTX
Website https://www.lavatherapeutics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LVTX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 48.15% from the latest price.
Stock Forecasts1 week ago
+7.89%
LAVA Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
+42.55%
Lava Therapeutics shares are trading higher after the company announced the evaluation of strategic options.
